Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma

Annals of Surgical Oncology

Volumn 13, Issue 3, 2006, Pages 340-346

  Gaca, Jeffrey G ^a   Petersen, Rebecca P ^a   Peterson, Bercedis L ^a   Harpole Jr , David H ^a   D'Amico, Thomas A ^a   Pappas, Theodore N ^a   Seigler, Hilliard F ^a   Wolfe, Walter G ^a   Tyler, Douglas S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Carcinoma; Chemotherapy; Gastroesophageal junction; Radiation

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL;

ADULT; AGE; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ESOPHAGUS CARCINOMA; FEMALE; HISTOLOGY; HUMAN; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTION; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 32844460355     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2006.02.023     Document Type: Article

References (28)

1. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus, gastric cardia. JAMA 1991; 265:1287-9.
2. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus, esophagogastric junction. Gastroenterology 1993; 104:510-3.
3. Wright CD, Mathisen DJ, Wain JC, et al. Evolution of treatment strategies for adenocarcinoma of the esophagus and gastroesophageal junction. Ann Thorac Surg 1994; 58:1574-8.
4. Lund O, Hasenkam JM, Aagaard MT, Kimose HH. Time-related changes in characteristics of prognostic significance in carcinomas of the oesophagus and cardia. Br J Surg 1989; 76:1301-7.
5. Papachristou D, Fortner JG. Adenocarcinoma of the gastric cardia: the choice of gastrectomy. Ann Surg 1980; 192:58-64.
6. Urba S, Orringer MB, Turrisi A, Iannetoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19:305-13.
7. Kelson D, Ginsburg R, Pajak TF, et al. Chemotherapy followed by surgery compared to surgery alone for localized esophageal cancer. N Engl J Med 1998; 339:1979-84.
8. Walsh T, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335:462-7.
9. Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992; 16:1104-9.
10. Law S, Fok M, Chow S, Chu KM, Wong J. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997; 114:210-7.
11. Wolfe WG, Burton GV, Seigler HF, Crocker IR, Vaughn AL. Early results with combined modality therapy for carcinoma of the esophagus. Ann Surg 1987; 205:563-71.
12. Wolfe WG, Vaughn AL, Seigler HF, Hathorn JW, Leopold KA, Duhaylongsod FG. Survival of patients with carcinoma of the esophagus treated with combined-modality therapy. J Thorac Cardiovasc Surg 1993; 105:749-55.
13. Siewert JR, Stein HJ. Carcinoma of the cardia: carcinoma of the gastroesophageal junction - classification, pathology, and extent of resection. Dis Esoph 1996; 9:173-82.
14. Steup WH, De Leyn P, Deneffe G, Van Raemdonck D, Coosemans W, Lerut T. Tumors of the esophagogastric junction. Long-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification. J Thorac Cardiovasc Surg 1996; 111:85-94.
15. Wijnhoven BP, Siersema PD, Hop WC, Dekken H, Tilanus HW. Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group. Br J Surg 1999; 86:529-35.
16. American Joint Committee on Cancer. Manual for Staging of Cancer. 5th ed. Philadelphia: JB Lippincott, 1997.
17. Kalish RJ, Clancy PE, Orringer MB, Appelman HD. Clinical, epidemiologic, and morphologic comparison between adenocarcinomas arising in Barrett's esophageal mucosa and in the gastric cardia. Gastroenterology 1984; 86:461-7.
18. Mendes de Almeida JC, Chaves P, Pereira AD, Altorki NK. Is Barren's esophagus the precursor of most adenocarcinomas of the esophagus and cardia? A biochemical study. Ann Surg 1997; 226:725-35.
19. Korst RJ, Rusch VW, Venkatraman E, et al. Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg 1998; 115:660-9.
20. Entwsitle J, Goldberg M. Multimodality therapy for resectable cancer of the esophagus. Ann Thorac Surg 2002; 73:1009-15.
21. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreatoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992; 127:1335-9.
22. Hoffman JP, Weese JL, Solin LJ, et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg 1995; 169:71-7.
23. Higgins GA, Humphrey EW, Dwight RW, Roswit B, Lee LE Jr, Keehn RJ. Preoperative radiation and surgery for cancer of the rectum. Veterans Administration Surgical Oncology Group Trial II. Cancer 1986; 58:352-9.
24. Swanson SJ, Batirel HF, Bueno R, et al. Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg 2001; 72:1918-24.
25. Alexander EP, Lipman T, Harmon J, Wadleigh R. Aggressive multimodality therapy for stage III esophageal cancer: a phase I/II study. Ann Thorac Surg 2000; 69:363-8.
26. Couper GW, McAteer D, Wallis F, et al. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg 1998; 85:1403-6.
27. Aloia TA, Harpole DH Jr, Reed CE, et al. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 2001; 72:859-66.
28. Duhaylongsod FG, Gottfried MR, Iglehart JD, Vaughn AL, Wolfe WG. The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg 1995; 221:677-83.